Kalaris Therapeutics

(NASDAQ) KLRS

Current Price$6.03

Market Cap$138.03M

Since IPO (2025)-48%

5 Year-99%

1 Year-10%

1 Month+12%

Kalaris Therapeutics Financials at a Glance

Market Cap

$138.03M

Revenue (TTM)

$0.00

Net Income (TTM)

$43.44M

EPS (TTM)

$-4.20

P/E Ratio

-1.44

Dividend

$0.00

Beta (Volatility)

1.35 (Average)

Dividend

$0.00

Beta (Volatility)

1.35 (Average)

Price

$6.03

Volume

Open

$6.06

Price

$6.03

Volume

Open

$6.06

Previous Close

$6.03

Daily Range

$6.03 - $6.07

52-Week Range

$2.14 - $11.88

Dividend

$0.00

Beta (Volatility)

1.35 (Average)

Price

$6.03

Volume

Open

$6.06

Previous Close

$6.03

Daily Range

$6.03 - $6.07

52-Week Range

$2.14 - $11.88

KLRS News

Kalaris Reports Loss Cash at 88 Million

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kalaris Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Andrew Oxtoby, MBA

Website

www.kalaristx.com

Headquarters

Cambridge, MA 02142, US

KLRS Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-45%

Return on Capital

-41%

Return on Assets

-36%

Earnings Yield

-69.44%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$138.03M

Shares Outstanding

22.93M

Volume

Avg. Volume

66.67K

Financials (TTM)

Gross Profit

$13.00K

Operating Income

$46.15M

EBITDA

$46.14M

Operating Cash Flow

$42.98M

Capital Expenditure

$200.00K

Free Cash Flow

$43.18M

Cash & ST Invst.

$117.98M

Total Debt

$1.45M

Kalaris Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$10.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$138.03M

N/A

Market Cap/Employee

$9.86M

N/A

Employees

N/A

Net Income

$10.00M

+45.3%

EBITDA

$10.79M

+40.9%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$116.53M

-1.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.13M

N/A

Short Term Debt

$316.00K

N/A

Return on Assets

-35.68%

N/A

Return on Invested Capital

-41.20%

N/A

Free Cash Flow

$9.33M

-115.7%

Operating Cash Flow

$9.32M

-115.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CNTBConnect Biopharma Holdings Limited

CNTBConnect Biopharma Holdings Limited$2.45-2.78%

IFRXInflaRx N.V.

IFRXInflaRx N.V.$1.61+8.78%

IMAImageneBio Inc

IMAImageneBio Inc$5.83+2.10%

CNTXContext Therapeutics Inc.

CNTXContext Therapeutics Inc.$2.34+3.54%

MGXMetagenomi, Inc. Common Stock

MGXMetagenomi, Inc. Common Stock$1.48-1.33%

ARTVArtiva Biotherapeutics, Inc.

ARTVArtiva Biotherapeutics, Inc.$10.75+4.17%

QNCXQuince Therapeutics, Inc.

QNCXQuince Therapeutics, Inc.$1.29-5.15%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

POETPoet Technologies

POETPoet Technologies$7.95-0.47%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$62.64+0.00%

NOKNokia

NOKNokia$10.71+0.03%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$52.45-0.00%

INTCIntel

INTCIntel$84.99+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$12.32+0.01%

QQQInvesco QQQ Trust

QQQInvesco QQQ Trust$664.23+0.00%

Questions About KLRS

What is the current price of Kalaris Therapeutics?

Kalaris Therapeutics is trading at $6.03 per share.

What is the 52-week range for Kalaris Therapeutics?

Over the past 52 weeks, Kalaris Therapeutics has traded between $2.14 and $11.88.

How much debt does Kalaris Therapeutics have?

As of the most recent reporting period, Kalaris Therapeutics reported total debt of $1.45M.

How much cash does Kalaris Therapeutics have on hand?

Kalaris Therapeutics reported $98.05M in cash and cash equivalents in its most recent financial results.

What is Kalaris Therapeutics’s dividend yield?

Kalaris Therapeutics does not currently have a dividend yield.

Kalaris Therapeutics

Kalaris Therapeutics Financials at a Glance

KLRS News

Kalaris Reports Loss Cash at 88 Million

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Kalaris Therapeutics

KLRS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Kalaris Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KLRS

What is the current price of Kalaris Therapeutics?

What is the 52-week range for Kalaris Therapeutics?

How much debt does Kalaris Therapeutics have?

How much cash does Kalaris Therapeutics have on hand?

What is Kalaris Therapeutics’s dividend yield?

Premium Investing Services